ACHN News and Press, Achison Inc Cl A

Investment Thesis The patent disputes over its leading revenue generator have taken its toll on Alexion Pharmaceuticals, Inc. ( ALXN ), with its share price lagging the peers as the company attempts to diversify the top-line. The recent acquisitions, driven by the rising cash flows and low...

Investment Thesis Alexion Pharmaceuticals, Inc. ( ALXN ) is yet to recover from the last year's patent challenges to the leading revenue generator, Soliris. Over the past twelve months, the stock has lost more than a fifth while the Nasdaq Biotechnology Index has gained nearly a tenth. See...

When looking at biotech stocks, a big point of focus should be on the products driving revenue now or the solidity of the pipeline, which will drive revenue later. Acadia Pharmaceuticals (NASDAQ: ACAD) , Alexion Pharmaceuticals (NASDAQ: ALXN) , and Seattle Genetics (NASDAQ: SGEN) are ...

January 28, 2020 Palm Beach, FL – January 28, 2020 – Brain and other nervous system cancers are the 10th leading cause of death for men and women. The global G lioblastoma multiforme  (GBM) drugs market to reach nearly $1.4 billion by 2025, expanding at a CAGR o...

Agile Therapeutics, Inc. (AGRX) is drawing close to an important milestone as the PDUFA date for its Twirla drug candidate is now right around the corner. The Food and Drug Administration is scheduled to announce its decision on February 16 th . The FDA was earlier supposed to pass the verdict...

Apellis Pharmaceuticals ( APLS ) reported positive phase 3 results of pegcetacoplan (APL-2) in PNH patients. Pegcetacoplan, the company's C3 inhibitor, managed to beat Alexion Pharmaceuticals' ( ALXN ) eculizumab (Soliris) on the primary endpoint and to show positive trends on multiple secon...

Merger activity decreased with one new deal announced, eight deals closing, and one deal falling apart. Deal Statistics: New Deals: We did not have any traditional mergers or acquisitions announced last week, and the only deal inked was the merger of a special purpose acquisition com...

2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...

Merger activity increased, with nine new deals announced and six deals closing. Deal Statistics New Deals The acquisition of LogMeIn (LOGM) by Francisco Partners for $4.3 billion or $86.05 per share in cash. We added LOGM as a potential deal to the Deals in the Works section on Dece...

BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have appr...